Abstract
To achieve effective drug concentration at the intended site for a sufficient period of time is a requisite desired for many drug formulations. For drugs intended to ocular delivery, its poor bioavailability is due to pre-corneal factors. Most ocular diseases are treated by topical drug application in the form of solution, suspension and ointment. However, such dosage forms are no longer sufficient to combat some ocular diseases. Intravitreal drug injection is the current therapy for disorders in posterior segment. The procedure is associated with a high risk of complications, particularly when frequent, repeated injections are required. Thus, sustained-release technologies are being proposed, and the benefits of using colloidal carriers in intravitreal injections are currently under investigation for posterior drug delivery. This review will discuss recent progress and specific development issues relating to colloidal drug delivery systems, such as liposomes, niosomes, nanoparticles, and microemulsions in ocular drug delivery.
Keywords: ophthalmic delivery, ocular bioavailability, colloidal drug delivery systems
Current Drug Targets
Title: Colloidal Carriers for Ophthalmic Drug Delivery
Volume: 6 Issue: 3
Author(s): Rubiana Mara Mainardes, Maria Cristina Cocenza Urban, Priscila Oliveira Cinto, Najeh Maissar Khalil, Marco Vinicius Chaud, Raul Cesar Evangelista and Maria Palmira Daflon Gremiao
Affiliation:
Keywords: ophthalmic delivery, ocular bioavailability, colloidal drug delivery systems
Abstract: To achieve effective drug concentration at the intended site for a sufficient period of time is a requisite desired for many drug formulations. For drugs intended to ocular delivery, its poor bioavailability is due to pre-corneal factors. Most ocular diseases are treated by topical drug application in the form of solution, suspension and ointment. However, such dosage forms are no longer sufficient to combat some ocular diseases. Intravitreal drug injection is the current therapy for disorders in posterior segment. The procedure is associated with a high risk of complications, particularly when frequent, repeated injections are required. Thus, sustained-release technologies are being proposed, and the benefits of using colloidal carriers in intravitreal injections are currently under investigation for posterior drug delivery. This review will discuss recent progress and specific development issues relating to colloidal drug delivery systems, such as liposomes, niosomes, nanoparticles, and microemulsions in ocular drug delivery.
Export Options
About this article
Cite this article as:
Mainardes Mara Rubiana, Urban Cristina Cocenza Maria, Cinto Oliveira Priscila, Khalil Maissar Najeh, Chaud Vinicius Marco, Evangelista Cesar Raul and Daflon Gremiao Palmira Maria, Colloidal Carriers for Ophthalmic Drug Delivery, Current Drug Targets 2005; 6 (3) . https://dx.doi.org/10.2174/1389450053765914
DOI https://dx.doi.org/10.2174/1389450053765914 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Anti-Shock Garments for Obstetric Hemorrhage
Current Women`s Health Reviews From the Obscure and Mysterious Acute Phase Response to Toll-Like Receptors and the Cytokine Network
Current Immunology Reviews (Discontinued) Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Non-Analgesic Effects of Opioids: Mechanisms and Potential Clinical Relevance of Opioid-Induced Immunodepression
Current Pharmaceutical Design Multiple Roles for Chemokines in the Pathogenesis of SIV Infection
Current HIV Research Implications of Kidney Disease on Metabolic Reduction
Current Drug Metabolism GABAergic Microcircuits in Alzheimer's Disease Models
Current Alzheimer Research Treatment of Leishmaniasis: A Review and Assessment of Recent Research
Current Pharmaceutical Design The Return of the INGs, Histone Mark Sensors and Phospholipid Signaling Effectors
Current Drug Targets ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Individual Differences and Vulnerability to Drug Addiction: A Focus on the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Enantioselective, Potentiometric Membrane Electrodes (EPME) Based on Maltodextrins for the Determination of L-Vesamicol in Serum Samples
Current Pharmaceutical Analysis Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors
Current Clinical Pharmacology Giardiasis in the Post Genomic Era: Treatment, Drug Resistance and Novel Therapeutic Perspectives
Infectious Disorders - Drug Targets Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Transcriptional Regulation as a Pharmacologic Intervention
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents